Why the study?
The mechanisms responsible for the effects of the (pro)renin receptor and YAP on diabetic cardiomyopathy remained unclear.
Population
Diabetic cardiomyopathy rat model and primary rat cardiac fibroblasts
Comparison
PRR and YAP modulation with or without GSK621
Design
Preclinical animal and in vitro study
Authors
Loading...
Hypothesis-generating for PRR-YAP inhibition in diabetic cardiomyopathy; requires clinical validation before any practice change.
Inhibition of the (pro)renin receptor (PRR) or YAP alleviates myocardial inflammation and fibrosis in diabetic cardiomyopathy via the PRR-AMPK-YAP pathway, offering a potential novel therapeutic target.
Xiong et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: